Global Health
- Market Cap
- ₹39,798 Cr
- P/E
- 64.33
Key Fundamentals
MidcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 17.40%
- Debt to Equity
- 0.31
- EPS (TTM)
- ₹23.01
- Book Value
- ₹160.82
- Market Cap
- ₹39,798 Cr
- P/E (TTM)
- 64.33
- P/B
- 9.20
- ROE
- 15.20%
- Dividend Yield
- 0.03%
- EBITDA
- ₹1,018 Cr
- 52W High
- ₹1,544.00
- 52W Low
- ₹956.00
- Day Range
- ₹1,472.20 – ₹1,509.30
- Volume
- 2,65,365
Peer Comparison
Healthcare › Healthcare Services › Hospital
| 9,200.00 | 59.00 | 1,32,282 | 12.47 | 0.23% | 21.50% | 17.40% | 27,630 | 2,337 | |
| 1,081.00 | 76.23 | 1,05,215 | 9.28 | 0.20% | 14.70% | 14.70% | 9,146 | 1,380 | |
| 702.20 | 101.77 | 92,366 | 6.01 | 0.00% | 6.72% | 8.30% | 12,370 | 873 | |
| 779.30 | 110.70 | 67,929 | 8.72 | 0.41% | 11.30% | 11.60% | 6,508 | 564 | |
| 825.00 | 59.96 | 62,284 | 5.94 | 0.13% | 11.20% | 13.40% | 9,910 | 1,061 | |
| 1,480.20 | 64.33 | 39,798 | 9.20 | 0.03% | 15.20% | 17.40% | 5,053 | 613 | |
| 1,943.70 | 46.25 | 39,722 | 7.94 | 0.24% | 20.50% | 15.50% | 10,273 | 859 | |
| Median 7 companies | 1,081.00 | 64.33 | 67,929 | 8.72 | 0.20% | 14.70% | 14.70% | 9,910 | 873 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 39
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 31
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 79
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 52
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 45
- Average
- Trend strength, vol-adjusted 12% weight
- Ownership
- 54
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has delivered good profit growth of 80.7% CAGR over last 5 years
Weaknesses
1- Stock is trading at 9.21 times its book value
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 3 | 13 |
| Oscillators | Neutral | 3 | 3 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Neutral
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 68.37
- Neutral
- MACD (12,26,9)
- 38.53
- Bullish
- SMA (50)
- 1,370.05
- Bullish
- SMA (200)
- 1,267.08
- Bullish
As of
Analyst Rating
15 of 16 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +12.30% |
|---|---|
| 5Y | +24.97% |
| 3Y | +17.62% |
| 1Y | +19.45% |
| TTM | +26.20% |
Net profit
| 10Y | +12.54% |
|---|---|
| 5Y | +80.39% |
| 3Y | +19.33% |
| 1Y | +15.18% |
| TTM | +9.27% |
Operating cash flow
| 10Y | +12.09% |
|---|---|
| 5Y | +24.16% |
| 3Y | +3.45% |
| 1Y | +14.42% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −0.69 pp |
|---|---|
| 5Y | +7.48 pp |
| 3Y | −2.42 pp |
| 1Y | −2.91 pp |
| TTM | −1.37 pp |
Revenue by year
| Mar 2016 | ₹1,382 Cr |
|---|---|
| Mar 2018 | ₹1,343 Cr |
| Mar 2019 | ₹1,456 Cr |
| Mar 2020 | ₹1,500 Cr |
| Mar 2021 | ₹1,447 Cr |
| Mar 2022 | ₹2,167 Cr |
| Mar 2023 | ₹2,710 Cr |
| Mar 2024 | ₹3,275 Cr |
| Mar 2025 | ₹3,692 Cr |
| Mar 2026 | ₹4,410 Cr |
Net profit by year
| Mar 2016 | ₹170 Cr |
|---|---|
| Mar 2018 | ₹33.00 Cr |
| Mar 2019 | ₹51.00 Cr |
| Mar 2020 | ₹36.00 Cr |
| Mar 2021 | ₹29.00 Cr |
| Mar 2022 | ₹196 Cr |
| Mar 2023 | ₹326 Cr |
| Mar 2024 | ₹478 Cr |
| Mar 2025 | ₹481 Cr |
| Mar 2026 | ₹554 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Global Health Ltd (Medanta) trades at ₹1,444.2 as of 2026-11-17 with a market cap of ₹38,830 crore and a P/E of 62.76x. The company has delivered strong profit growth of roughly 81% CAGR over five years and maintains a low debt-to-equity ratio of 0.30, but its valuation at 8.98x book value and a TTM P/E north of 60x place it at a significant premium to broader market averages.
- Exceptional 5-year compounded profit growth of 81%, reflecting a strong earnings trajectory as hospital operations scaled up
- Robust 5-year compounded sales growth of 25%, with TTM sales growth accelerating further to 26%, indicating sustained demand momentum
- Conservative balance sheet with a debt-to-equity ratio of just 0.30, providing financial flexibility for expansion without heavy leverage
- ROCE of 15.05% suggests efficient deployment of capital across hospital assets, a positive sign for a capital-intensive healthcare business
- 3-year stock CAGR of 17% and 1-year stock CAGR of 21% show the market has consistently rewarded the company's operational performance
- 3-year compounded profit growth of 19% and 3-year compounded sales growth of 18% demonstrate that growth has continued beyond a one-time post-pandemic recovery
- ROE has been consistently around 15-16% over the last three and five years, indicating steady return generation for shareholders despite rapid expansion
- Trading at a P/E of 62.76x on a TTM basis, which is well above typical large-cap healthcare peers and leaves little room for earnings disappointment
- Price-to-book ratio of 8.98x is elevated, meaning the stock prices in substantial future growth that must be delivered to justify the premium
- TTM profit growth has decelerated to 11% from the 3-year CAGR of 19%, raising questions about whether the high-growth phase is moderating
- Dividend yield of just 0.03% offers virtually no income return, making the stock entirely dependent on capital appreciation
- ROE of 13.91% (current) is modest relative to the lofty valuation multiples; a P/B of nearly 9x typically demands meaningfully higher return on equity
- 10-year compounded profit growth of 13% and 10-year sales growth of 12% show that the longer-term base rate of growth is far more moderate than recent 5-year figures suggest
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Global Health delivered a strong Q2FY27 with 38% profit growth and margin expansion to 25.2%, signalling robust operational momentum. However, back-to-back senior exits — the Gurugram Hospital Director leaving to a competitor and the HR head resigning — flag potential leadership churn risk. The scheduled analyst meetings may provide further clarity on growth trajectory and management stability. The earnings trend is positive, but retention of key talent at flagship units bears watching.
- Hospital Director exits to competitor Oct 31
Dr. Pankaj Dhamija, Hospital Director at Medanta Gurugram, resigned effective October 30, 2026, with departure accelerated due to planned competition — a potential talent and operational continuity risk at a flagship unit.
- Q2 PAT up 38%, margins expand Nov 3
Global Health reported Q2FY27 net profit of ₹2,191 million, up 38.3% YoY. Operating EBITDA margin expanded to 25.2%, driven by strong volume growth.
- Analyst meetings scheduled Nov 16-17 Nov 10
Global Health will hold one-to-one meetings with nine institutional investors and analysts on November 16-17, 2026, in person.
- HR head resigns, ESOPs granted Nov 2
SVP & Head-HR Saurabh Upadhyay resigned effective December 23, 2026. The company also granted 3.14 lakh ESOPs at ₹635 per share.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 | 1,469 |
| Expenses | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 | 1,099 |
| Operating Profit | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 | 370 |
| OPM % | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% | 25% |
| Other Income | 21 | 18 | 27 | 22 | 18 | 16 | 22.93 | 20 | 19.73 | 21.78 | 37 | 22 | 23.62 |
| Interest | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 | 28.09 |
| Depreciation | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 | 70.8 |
| Exceptional Items | — | — | — | — | — | — | −49.9 | — | 15.99 | −36.6 | — | — | — |
| PBT | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 | 295 |
| Tax % | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% | 26% |
| Net Profit | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 | 219 |
| EPS (₹) | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.90 | 8.21 |
| YoY Sales growth | 24 | 20 | 14 | 10 | 13 | 13 | 15 | 20 | 15 | 19 | 24 | 26 | 34 |
Profit & Loss
₹ Cr| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 | 5,053 |
| Expenses | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,480 | 3,935 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 930 | 1,118 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 21% | 22% |
| Other Income | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 79.1 | 98.59 | 68 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 90 | 103 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 | 267 |
| Exceptional Items | — | — | — | — | — | — | — | — | −49.9 | — | — |
| PBT | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 | 815 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | 23% | — |
| Net Profit | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 | 613 |
| EPS (₹) | 6.72 | 1.30 | 2.03 | 1.43 | 1.14 | 7.75 | 12.16 | 17.81 | 17.92 | 20.70 | 23.01 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% | — |
| Sales growth | — | — | 8 | 3 | −4 | 50 | 25 | 21 | 13 | 19 | 26 |
Balance Sheet
₹ Cr| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,908 | 4,270 |
| Borrowings | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 1,190 | 1,353 |
| Other Liabilities | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 | 930 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 | 6,606 |
| Fixed Assets | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 | 3,957 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 | 207 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 |
| Other Assets | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,975 | 2,440 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 | 6,606 |
Cash Flow
₹ Cr| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Investing | −241 | −69 | −249 | −87 | −239 | −421 | −342 | −441 | −721 | −1,089 |
| Financing | −7 | 9 | 97 | −1 | −81 | 160 | 346 | −514 | −97 | 272 |
| Net Cash Flow | −20 | 3 | 14 | 87 | −78 | 50 | 648 | −343 | −194 | −103 |
| Free Cash Flow | 71 | −81 | −133 | −13 | 100 | 38 | 409 | 335 | 110 | −123 |
| CFO/EBITDA | 108 | 93 | 135 | 121 | 131 | 89 | 118 | 98 | 89 | 90 |
Ratios
| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 | 34 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 | 29 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 | 89 |
| Cash Conversion Cycle | −45 | −56 | −75 | −67 | −62 | −24 | −52 | −34 | −24 | −26 |
| Working Capital Days | −23 | −33 | −18 | −31 | −48 | −20 | −37 | −32 | −21 | −7 |
| ROCE % | — | — | 6% | 6% | 5% | 15% | 17% | 20% | 20% | 17% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Global Health insights
65 extracted metrics across FY16–FY27.
Documents
- Q2 FY27 concall · Nov 2026PPT
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Concall · May 2026Transcript PPT Recording
- 30 Jul 2026
- 18 Nov 2026
- 16 Dec 2025
- 16 Oct 2025
- 17 Mar 2025
- 4 Feb 2025
- General announcements 18 Nov 2026
- General announcements 16 Nov 2026
- General announcements 10 Nov 2026
Frequently Asked Questions about Global Health
What does Global Health Ltd do?
Where is Global Health Ltd (MEDANTA) listed?
Which sector does Global Health Ltd belong to?
What is the market capitalisation of Global Health Ltd?
What is the PE ratio of Global Health Ltd?
What is the 52-week high and low of Global Health Ltd?
Does Global Health Ltd pay dividends?
What is the Return on Equity (ROE) of Global Health Ltd?
Company Information
Global Health Limited operates a network of multi-specialty tertiary and quaternary care hospitals under the Medanta brand, primarily across North and East India. The company specialises in cardiac sciences, oncology, neurosciences, digestive and hepatobiliary sciences, orthopaedics, organ transplantation, kidney and urology, and other complex medical procedures. As of June 2026, Medanta operated six hospitals across Gurugram, Lucknow, Patna, Ranchi, Indore and Noida, supported by an expanding diagnostics, pharmacy and outpatient network.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDANTA.md for Global Health Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.